Dimethyloxallyl Glycine-Incorporated Borosilicate Bioactive Glass Scaffolds for Improving Angiogenesis and Osteogenesis in Critical-Sized Calvarial Defects

(E-pub Ahead of Print)

Author(s): Xiangyun Jin, Dan Han, Jie Tao, Yinjun Huang, Zihui Zhou, Zheng Zhang*, Xin Qi*, Weitao Jia*.

Journal Name: Current Drug Delivery

Become EABM
Become Reviewer


In the field of bone tissue engineering, there has been an increasing interest in biomedical materials with both high angiogenic ability and osteogenic ability. Among various osteogenesis materials, bioactive borosilicate and borate glass scaffolds possess suitable degradation rate and mechanical strength, thus drawing many scholars’ interests and attention. In this study, we fabricated bioactive glass scaffolds composed of borosilicate 2B6Sr using the Template-Method and incorporated Dimethyloxalylglycine (DMOG), a small-molecule angiogenic drug possessing good angiogenic ability, to improve bone regeneration. The in-vitro studies showed that porous borosilicate bioactive glass scaffolds releases a slow, steady amount of DMOG and stimulated the proliferation and osteogenic differentiation of human bone marrow stromal cells hBMSCs. In-vivo studies showed that the borosilicate bioactive glass scaffolds could significantly promote new bone formation and neovascularization in rats’ calvarial bone defects. These results indicated that DMOG-incorporated bioactive glass scaffold was a successful compound with excellent angiogenesis–osteogenesis ability, which has favorable clinical prospects.

Keywords: Dimethyloxallyl glycine, Borosilicate bioactive glass, Osteogenesis, Angiogenesis, Bone regeneration

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1567201816666190611105205
Price: $95

Article Metrics

PDF: 2